Sun Pharma Advanced Research Company Terminates License Agreement with CMS Bridging DMCC
Sun Pharma Advanced Research Company Limited has announced the mutual termination of a License Agreement with CMS Bridging DMCC (CMS). The agreement, which was originally executed on November 05, 2019, concluded on June 25, 2026.The License Agreement focused on the development and commercialization of several products in Mainland China, Hong Kong, Macao, and Taiwan. These products included Xelpros TM, Elepsia TM, Taclantis TM, PDP-716, and SDN-037.
The company stated that there is no material impact on its financial position, operations, or other activities following the termination of the agreement with CMS Bridging DMCC.
Key details regarding the terminated partnership are summarized below:
| Aspect | Details |
|---|---|
| Partner | CMS Bridging DMCC (CMS) |
| Original Agreement Date | November 05, 2019 |
| Termination Date | June 25, 2026 |
| Agreement Purpose | To develop and commercialize products including Xelpros TM, Elepsia TM, Taclantis TM, PDP-716, and SDN-037 in Mainland China, Hong Kong, Macao, and Taiwan. |
| Impact Statement | No material impact on the Company's financial position or operations due to the termination. |
SPARC Stock Price Movement
On Thursday, shares of Sun Pharma Advanced Research Company Limited slipped by 1.04% to settle at ₹224.92, shedding ₹2.36 in the session. The stock saw a traded volume of 2,065,558 shares during the trading period.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.